Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Charles River Laboratories Inte
CRL
$292.84
Name : Charles River Laboratories Inte
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $14,105,437,184.00
EPSttm : -4.8
finviz dynamic chart for CRL
Charles River Laboratories Inte
$292.84
0.54%
$1.60
CRL — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

4.73

Margin Of Safety %

-22

Put/Call OI Ratio

0.46

EPS Next Q Diff

0.29

EPS Last/This Y

14.24

EPS This/Next Y

1.38

Price

293.03

Target Price

306.07

Analyst Recom

1.85

Performance Q

35.89

Upside

-136.4%

Beta

1.41

Ticker: CRL




20 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-08-28CRL291.510.371.696045
2026-08-31CRL288.670.400.596461
2026-09-01CRL282.410.401.196513
2026-09-02CRL291.810.400.136548
2026-09-03CRL293.370.405.866596
2026-09-04CRL288.610.390.066589
2026-09-08CRL280.920.390.316593
2026-09-09CRL278.390.400.646819
2026-09-10CRL273.170.392.756890
2026-09-11CRL278.320.400.766925
2026-09-14CRL272.990.409.006882
2026-09-15CRL272.730.5386.007710
2026-09-16CRL273.520.475.797558
2026-09-17CRL281.640.750.068775
2026-09-18CRL278.010.720.909058
2026-09-21CRL279.250.370.756057
2026-09-22CRL285.170.380.806153
2026-09-23CRL277.330.391.116339
2026-09-24CRL294.490.401.116726
2026-09-25CRL293.150.460.646929
DateSymbolLatestP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-08-28CRL291.4221.5459.911.32
2026-08-31CRL288.3121.5461.811.32
2026-09-01CRL282.3421.5458.811.32
2026-09-02CRL291.7321.5699.011.32
2026-09-03CRL293.4521.5685.311.32
2026-09-04CRL288.5421.5674.211.32
2026-09-08CRL280.8621.5669.111.32
2026-09-09CRL278.0021.5677.511.32
2026-09-10CRL273.0221.5672.811.32
2026-09-11CRL278.2121.5691.811.32
2026-09-14CRL273.0621.5673.011.32
2026-09-15CRL272.6121.5681.411.32
2026-09-16CRL272.6121.5681.411.32
2026-09-17CRL281.6721.5697.411.32
2026-09-18CRL277.9221.5675.711.32
2026-09-21CRL279.1021.5684.211.32
2026-09-22CRL285.1921.5693.411.33
2026-09-23CRL277.3921.5668.811.33
2026-09-24CRL294.5121.5713.211.33
2026-09-25CRL293.0321.4680.011.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-08-28CRL-23.85-1.625.00
2026-08-31CRL-23.85-1.615.00
2026-09-01CRL-23.85-1.615.00
2026-09-02CRL-23.85-1.615.00
2026-09-03CRL-23.85-1.615.00
2026-09-04CRL-23.85-1.615.00
2026-09-08CRL-23.85-1.535.00
2026-09-09CRL-23.85-1.535.00
2026-09-10CRL-23.69-1.535.00
2026-09-11CRL-23.69-1.535.37
2026-09-14CRL-23.69-1.925.37
2026-09-15CRL-23.69-1.925.37
2026-09-16CRL-23.69-1.925.37
2026-09-17CRL-23.69-1.925.37
2026-09-18CRL-23.69-1.925.37
2026-09-21CRL-23.69-1.925.37
2026-09-23CRL-23.69-1.925.37
2026-09-24CRL-23.69-1.925.37
2026-09-25CRL-23.69-1.924.73
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS​

3.02

Avg. EPS Est. Current Quarter

2.95

Avg. EPS Est. Next Quarter

3.31

Insider Transactions

-23.69

Institutional Transactions

-1.92

Beta

1.41

Average Sales Estimate Current Quarter

958

Average Sales Estimate Next Quarter

952

Fair Value

229.45

Quality Score

43

Growth Score

50

Sentiment Score

87

Actual DrawDown %

35.7

Max Drawdown 5-Year %

-78.2

Target Price

306.07

P/E

Forward P/E

23.01

PEG

2.04

P/S

3.5

P/B

4.93

P/Free Cash Flow

37.76

EPS

-4.85

Average EPS Est. Cur. Y​

11.33

EPS Next Y. (Est.)

12.71

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-5.96

Relative Volume

0.88

Return on Equity vs Sector %

-34.7

Return on Equity vs Industry %

-19.9

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

680
◆ CRL Healthcare
$293.18
📉
Swing / Pullback
Buy the dip on strong trends
57 /100
WATCH
Trend
20/20
Pullback
12/25
Volume
7/15
Valuation
8/20
TP/AR
3/10
Options
7/10
RSI
60.2
Range 1M
69.7%
Sup Dist
4%
🚀
Momentum Growth
Ride accelerating trends
N/A
39 /100
WEAK
Momentum
13/25
Growth
10/30
Estimates
4/20
Inst/Vol
4/15
Options
8/10
EPS Yr
10.3%
EPS NY
12.4%
52W%
93.1%
💎
Long-Term Value
Quality companies, undervalued
N/A
0 /100
WEAK
🔴 SELL -7.9% upside
Quality
6/30
Valuation
1/30
Growth
10/25
Stability
3/10
LT Trend
4/5
Upside
-7.9%
Quality
43
MoS
-22%
CRL — P/E HistoricalDiagnostics & Research
Charles River Laboratories Inte
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 18300
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has strategic collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Additionally, it has a strategic alliance with Francis Crick Institute (Crick), Inc. for the development of Antibody-Drug Conjugate (ADC) drug discovery and development. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CRL

Latest News

—
Caricamento notizie per CRL…
stock quote shares CRL – Charles River Laboratories International, Inc. Stock Price stock today
news today CRL – Charles River Laboratories International, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CRL – Charles River Laboratories International, Inc. yahoo finance google finance
stock history CRL – Charles River Laboratories International, Inc. invest stock market
stock prices CRL premarket after hours
ticker CRL fair value insiders trading